Leerink Partners analyst Puneet Souda maintained a Buy rating on CryoPort (NASDAQ:CYRX) Inc on Wednesday, setting a price target of $75, which is approximately 18.99% above the present share price of $63.03.
Souda expects CryoPort Inc to post earnings per share (EPS) of -$0.13 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in CryoPort, with an average price target of $79.25.
The analysts price targets range from a high of $84 to a low of $75.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $53.28 million and a net profit of -$1.14 million. The company's market cap is $2.87 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.2% and a 60.63% success rate.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.